商品编号


4670-500-01



品牌


Trevigen



公司


Trevigen, Inc



公司分类


DNA Damage



Size

500 μl

商品信息

Description

CONCENTRATION
250 μM in deionized water.

Extinction Coefficient
E
mM
(265 nM)=22
1083.93 g/mole (1060.94 g/mole as a free acid)

STORAGE
Store at -80°C.

APPLICATIONS
Activity measurements of NAD+-requiring enzymes.
Assays to identify inhibitors of NAD+-requiring enzymes.

Bacillus cereus Certhrax ADP-ribosylates Vinculin to Disrupt Focal Adhesion Complexes and Cell Adhesion,
Nathan C. Simon and Joseph T. Barbieri
J. Biol. Chem., Apr 2014; 289: 10650 – 10659.
http://www.jbc.org/cgi/content/abstract/289/15/10650

The oligonucleotide/oligosaccharide-binding fold motif is a poly(ADP-ribose)-binding domain that mediates DNA damage response
Zhang, F., Chen, Y., Li, M. and Yu, X.
PNAS, May 2014; 111: 7278 – 7283.
http://www.pnas.org/cgi/content/abstract/111/20/7278

BEC, a Novel Enterotoxin of Clostridium perfringens Found in Human Clinical Isolates from Acute Gastroenteritis Outbreaks
Shinya Yonogi, Shigeaki Matsuda, Takao Kawai, Tomoko Yoda, Tetsuya Harada, Yuko Kumeda, Kazuyoshi Gotoh, Hirotaka Hiyoshi, Shota Nakamura, Toshio Kodama, and Tetsuya Iida
Infect. Immun., Jun 2014; 82: 2390 – 2399.
http://iai.asm.org/cgi/content/abstract/82/6/2390

NAD-dependent ADP-ribosylation of the human antimicrobial and immune-modulatory peptide LL-37 by ADP-ribosyltransferase-1
Monica Picchianti, Carla Russo, Marta Castagnini, Massimiliano Biagini,
ELISA
betta Soldaini, and Enrico Balducci
Innate Immunity, Aug 2014; 10.1177/1753425914536242.
http://ini.sagepub.com/cgi/content/abstract/1753425914536242v1

Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment
Minghai Zhou, Gregory Ottenberg, Gian Franco Sferrazza, Christopher Hubbs, Mohammad Fallahi, Gavin Rumbaugh, Alicia F. Brantley, and Corinne I. Lasme?zas
Brain, Feb 2015; 10.1093/brain/awv002.
http://brain.oxfordjournals.org/cgi/content/abstract/awv002v1

Tankyrase-mediated β-catenin activity regulates vasopressin-induced AQP2 expression in kidney collecting duct mpkCCDc14 cells
Hyun Jun Jung, Sang-Yeob Kim, Hyo-Jung Choi, Eui-Jung Park, Jung-Suk Lim, J?rgen Fr?kiaer, S?ren Nielsen, and Tae-Hwan Kwon
Am J Physiol Renal Physiol, Mar 2015; 308: F473 – F486.
http://ajprenal.physiology.org/cgi/content/abstract/308/5/F473

Structural Basis for Lack of ADP-ribosyltransferase Activity in Poly(ADP-ribose) Polymerase-13/Zinc Finger Antiviral Protein
Tobias Karlberg, Mirjam Klepsch, Ann-Gerd Thorsell, C. David Andersson, Anna Linusson, and Herwig Schu?ler
J. Biol. Chem., Mar 2015; 290: 7336 – 7344.
http://www.jbc.org/cgi/content/abstract/290/12/7336

“Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in
vivo by NAD+ replenishment”
Minghai Zhou, Gregory Ottenberg, Gian Franco Sferrazza, Christopher Hubbs, Mohammad Fallahi, Gavin Rumbaugh, Alicia F. Brantley, and Corinne I. Lasme?zas
Brain, Apr 2015; 138: 992 – 1008.
http://brain.oxfordjournals.org/cgi/content/abstract/138/4/992

“Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins”
Xiufen Liu, F
ABI
an Mu?ller, Alan S. Wayne, and Ira Pastan
Mol. Cancer Ther., May 2016; 15: 1053 – 1062.
http://mct.aacrjournals.org/cgi/content/abstract/15/5/1053

“Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage”
Jamin D. Steffen, Michael M. McCauley, and John M. Pascal
Nucleic Acids Res., Aug 2016; 10.1093/nar/gkw710.
http://nar.oxfordjournals.org/cgi/content/abstract/gkw710v1

“The NarE protein of Neisseria gonorrhoeae catalyzes ADP-ribosylation of several ADP-ribose acceptors despite an N-terminal deletion”
“Paula I. Rodas, A. Said ?lamos-Musre, Francisca P. ?lvarez, Alejandro Escobar, Cecilia V. Tapia, Eduardo
Osorio, Carolina Otero, Iván L. Calderón, Juan A. Fuentes, Fernando Gil, Daniel Paredes-Sabja, and Myron Christodoulides”
FEMS Microbiol Lett, Aug 2016; 363: fnw181
http://femsle.oxfordjournals.org/cgi/content/abstract/363/17/fnw181

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Toler
ABI
lity with Chemotherapy in Preclinical Models
“Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron N. Cranston, Rajesh Odedra, Henry Brown, Janneke E.
Jaspers, Louise Jones, Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic,
Sven Rottenberg, Jos Jonkers, David Rudge, Niall M.B. Martin, Keith W. Caldecott, Alan Lau, and Mark J.
O’Connor”
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein, so AZD2461 was developed as a poor substrate for drug transporters. Here we demonstrate the efficacy of this compound against olaparib-resistant tumors that overexpress P-glycoprotein. In addition, AZD2461 was better tolerated in combination with chemotherapy than olaparib in mice, which suggests that AZD2461 could have significant advantages over olaparib in the clinic. However, this superior toxicity profile did not extend to rats. Investigations of this difference revealed a differential PARP3 inhibitory activity for each compound and a higher level of PARP3 expression in bone marrow cells from mice as compared with rats and humans. Our findings have implications for the use of mouse models to assess bone marrow toxicity for DNA-damaging agents and inhibitors of the DNA damage response. Finally, structural modeling of the PARP3-active site with different PARP inhibitors also highlights the potential to develop compounds with different PARP family member specificity profiles for optimal antitumor activity and toler
ABI
lity. Cancer Res; 76(20); 6084-94. (C)2016 AACR.
http://cancerres.aacrjournals.org/cgi/content/abstract/76/20/6084

Wide Vari
ABI
lity in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design
F
ABI
an Mu?ller, Tyler Cunningham, Xiu Fen Liu, Alan S. Wayne, and Ira Pastan
Clin. Cancer Res., Oct 2016; 22: 4913 – 4922
http://clincancerres.aacrjournals.org/cgi/content/abstract/22/19/4913

Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage
Jamin D. Steffen, Michael M. McCauley, and John M. Pascal
Nucleic Acids Res., Nov 2016; 44: 9771 – 9783
http://nar.oxfordjournals.org/cgi/content/abstract/44/20/9771